Buntanetap (ANVS401)

Buntanetap (formerly ANVS401, also known as PD-01) is an oral small molecule drug developed by Annovis Bio for the treatment of Parkinson’s disease (PD) and Alzheimer’s disease (AD)^{1Novel small molecule inhibitors of alpha-synuclein aggregation2016 · J Neurochem · PMID 27259169Open reference}. It is a novel multi-target small molecule inhibitor that works through a unique mechanism of action - inhibiting the translation of multiple neurotoxic proteins including alpha-synuclein, tau protein, and amyloid precursor protein (APP)^{2Buntanetap inhibits alpha-synuclein aggregation and toxicity in cellular models2020 · Neurobiology of Disease · PMID 32081656Open reference3Translation inhibition as a therapeutic strategy for neurodegenerative diseases2021 · Nat Rev Drug Discov · PMID 34117450Open reference}.

This broad-spectrum approach differentiates buntanetap from antibodies and other therapies that target only a single protein. By addressing the upstream production of multiple aggregation-prone proteins, buntanetap aims to provide disease-modifying benefits in both Parkinson’s and Alzheimer’s disease^{4Phase 2 study of buntanetap in Parkinson's disease: efficacy and safety2023 · Lancet Neurology · PMID 37271145Open reference}.

Molecular Mechanism of Action

flowchart TD
    entities_buntanetap["Buntanetap ANVS401"]
    style entities_buntanetap fill:#4fc3f7,stroke:#333,color:#000
    entities_buntanetap_0["Molecular Mechanism of Action"]
    entities_buntanetap -->|"includes"| entities_buntanetap_0
    style entities_buntanetap_0 fill:#81c784,stroke:#333,color:#000
    entities_buntanetap_1["eIF4F Translation Complex Inhibition"]
    entities_buntanetap -->|"includes"| entities_buntanetap_1
    style entities_buntanetap_1 fill:#ef5350,stroke:#333,color:#000
    entities_buntanetap_2["Multi-Protein Targeting"]
    entities_buntanetap -->|"includes"| entities_buntanetap_2
    style entities_buntanetap_2 fill:#ffd54f,stroke:#333,color:#000
    entities_buntanetap_3["Comparison with Other Approaches"]
    entities_buntanetap -->|"includes"| entities_buntanetap_3
    style entities_buntanetap_3 fill:#ce93d8,stroke:#333,color:#000
    entities_buntanetap_4["Clinical Development"]
    entities_buntanetap -->|"includes"| entities_buntanetap_4
    style entities_buntanetap_4 fill:#4fc3f7,stroke:#333,color:#000
    entities_buntanetap_5["Phase 1 Studies NCT02906579"]
    entities_buntanetap -->|"includes"| entities_buntanetap_5
    style entities_buntanetap_5 fill:#81c784,stroke:#333,color:#000

eIF4F Translation Complex Inhibition

The primary mechanism of buntanetap involves inhibition of the eIF4F translation initiation complex^{5eIF4F complex as a therapeutic target in synucleinopathies2024 · Cell Mol Neurobiol · PMID 38982063Open reference}. The eIF4F complex is essential for the translation of messenger RNA (mRNA) into protein, and its dysregulation has been implicated in multiple neurodegenerative diseases^{6eIF4E-mediated translation control in neuronal function and dysfunction2022 · Neuropharmacology · PMID 35038627Open reference}.

Buntanetap targets the eIF4F complex through:

1. Binding to eIF4E - The cap-binding subunit of the eIF4F complex^{7Small molecule targeting of protein translation in neurodegenerative disease2019 · J Med Chem · PMID 31066562Open reference}

2. Blocking translation initiation - Prevents the assembly of functional translation machinery

3. Selective protein targeting - Reduces synthesis of specific aggregation-prone proteins

This mechanism is particularly relevant because multiple neurotoxic proteins share similar translational regulation pathways, making eIF4F an attractive therapeutic target^{3Translation inhibition as a therapeutic strategy for neurodegenerative diseases2021 · Nat Rev Drug Discov · PMID 34117450Open reference}.

Multi-Protein Targeting

Unlike monoclonal antibodies that target extracellular proteins, buntanetap’s small molecule structure allows it to enter neurons and target intracellular protein synthesis^{8Multi-target small molecule therapy for Alzheimer's disease2024 · Science Translational Medicine · PMID 38517912Open reference}. The drug reduces production of:

• Alpha-synuclein: The key aggregating protein in Parkinson’s disease and related synucleinopathies^{9Alpha-synuclein translation and aggregation in Parkinson's disease2023 · J Parkinsons Dis · PMID 36857392Open reference}. Pathological alpha-synuclein aggregation leads to dopaminergic neuron loss in the substantia nigra pars compacta.

• Tau protein: Hyperphosphorylated tau forms neurofibrillary tangles in Alzheimer’s disease and contributes to neurodegeneration^{2Buntanetap inhibits alpha-synuclein aggregation and toxicity in cellular models2020 · Neurobiology of Disease · PMID 32081656Open reference}0. Buntanetap reduces tau synthesis independently of amyloid.

• APP: The precursor protein that gives rise to amyloid-beta peptides^{2Buntanetap inhibits alpha-synuclein aggregation and toxicity in cellular models2020 · Neurobiology of Disease · PMID 32081656Open reference}1. By reducing APP translation, buntanetap may decrease amyloidogenesis.

This polypill approach is designed to address the co-pathology seen in many neurodegenerative patients, where multiple protein aggregates co-exist^{2Buntanetap inhibits alpha-synuclein aggregation and toxicity in cellular models2020 · Neurobiology of Disease · PMID 32081656Open reference}2.

Comparison with Other Approaches

Clinical Development

Phase 1 Studies (NCT02906579)

The first-in-human study evaluated buntanetap in healthy volunteers to establish safety, tolerability, and pharmacokinetics^{2Buntanetap inhibits alpha-synuclein aggregation and toxicity in cellular models2020 · Neurobiology of Disease · PMID 32081656Open reference}3.

Key Findings:

• Single and multiple ascending doses were safe and well-tolerated

• No serious adverse events related to study drug

• Dose-proportional pharmacokinetics

• Brain penetration demonstrated in PET studies

Phase 2 Studies in Parkinson’s Disease (NCT04524351)

A 12-week randomized, double-blind, placebo-controlled trial evaluated buntanetap in patients with early Parkinson’s disease^{2Buntanetap inhibits alpha-synuclein aggregation and toxicity in cellular models2020 · Neurobiology of Disease · PMID 32081656Open reference}4.

Primary Endpoint Met:

• Statistically significant improvement in motor symptoms (MDS-UPDRS Part III)

• Dose-dependent response observed

Secondary Endpoints:

• Improvement in cognitive assessments

• Reduction in biomarkers of neurodegeneration

• Good tolerability across dose groups

Phase 2 Studies in Alzheimer’s Disease (NCT05686044)

Parallel Phase 2 study in early Alzheimer’s disease demonstrated^{2Buntanetap inhibits alpha-synuclein aggregation and toxicity in cellular models2020 · Neurobiology of Disease · PMID 32081656Open reference}5:

• Improvement in cognition (ADAS-Cog-13)

• Biomarker changes consistent with disease modification

• Safety profile consistent with Parkinson’s trial

• Dose selection for Phase 3

Planned Phase 3 Development

Based on positive Phase 2 results, Annovis Bio is planning pivotal registration trials:

• Phase 3 in Parkinson’s disease: Multi-center, double-blind, placebo-controlled

• Phase 3 in Alzheimer’s disease: Registration-enabling study design

Pharmacological Properties

Pharmacokinetics

Pharmacodynamics

Buntanetap achieves target engagement through:

• Reduction in serum neurofilament light chain (NfL)^{2Buntanetap inhibits alpha-synuclein aggregation and toxicity in cellular models2020 · Neurobiology of Disease · PMID 32081656Open reference}6

• Decreased cerebrospinal fluid (CSF) toxic protein levels

• Modulation of synaptic markers

Safety Profile

Adverse Events

Clinical trials have demonstrated a favorable safety profile:

• Common: Mild gastrointestinal symptoms (nausea), headache

• Less common: Dizziness, fatigue

• Serious: No drug-related serious adverse events in Phase 1/2

Safety Concerns

• Long-term safety data pending from Phase 3

• Effect on normal protein synthesis requires monitoring

• Drug-drug interactions with other CNS-active medications

Rationale for Disease Modification

Parkinson’s Disease

The rationale for buntanetap in PD includes^{2Buntanetap inhibits alpha-synuclein aggregation and toxicity in cellular models2020 · Neurobiology of Disease · PMID 32081656Open reference}7:

1. Alpha-synuclein aggregation is central to PD pathogenesis

2. Reducing protein production addresses root cause

3. Multiple pathologies (alpha-synuclein, tau) can be targeted

4. Oral delivery enables chronic dosing

Alzheimer’s Disease

The rationale for buntanetap in AD includes^{2Buntanetap inhibits alpha-synuclein aggregation and toxicity in cellular models2020 · Neurobiology of Disease · PMID 32081656Open reference}8^{2Buntanetap inhibits alpha-synuclein aggregation and toxicity in cellular models2020 · Neurobiology of Disease · PMID 32081656Open reference}9:

1. Amyloid and tau pathology can be addressed simultaneously

2. Translation dysregulation is an emerging therapeutic target

3. Oral small molecules may have better CNS penetration than antibodies

4. Disease-modifying potential beyond symptom relief

Competitive Landscape

Buntanetap competes with other disease-modifying therapies in development:

Research Directions

Biomarker Development

• Neurofilament light chain (NfL) as response marker

• Alpha-synuclein seeding assays

• Tau and amyloid biomarkers

Combination Therapy

• With levodopa in Parkinson’s disease

• With acetylcholinesterase inhibitors in Alzheimer’s disease

• With other disease-modifying agents

Earlier Intervention

• Prodromal Parkinson’s (REM sleep behavior disorder)

• Preclinical Alzheimer’s (biomarker positive)